Because DLI can be administered only after a minimum of 3–4 months after relapse and the early AML relapse post-ASCT showed the poorest outcome, several studies have addressed the possibility of using G-CSF-mobilized peripheral blood mononuclear cells to produce DLI due to the immune regulatory effects of G-CSF [26]. This evidence concerns the gene CSF3 and acute myeloid leukemia.